torasemide ER / Sarfez Pharma - LARVOL DELTA

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial

NEXT-HF: Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (clinicaltrials.gov) - P4 | N=20 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

EXTOR-HF: A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs (clinicaltrials.gov) - P4 | N=5 | Terminated | Sponsor: Sarfez Pharmaceuticals, Inc. | N=26 ➔ 5 | Trial completion date: Nov 2025 ➔ Mar 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2025 ➔ Mar 2025; Issues with recruitment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Extended Release Torsemide in Patients with Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Withdrawn ➔ Recruiting | Trial completion date: Mar 2025 ➔ Jul 2026 | Trial primary completion date: Mar 2025 ➔ Jul 2026

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=24 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: Sarfez Pharmaceuticals, Inc. | Withdrawn ➔ Terminated; Issues with recruitment

Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=26 ➔ 0 | Trial completion date: Aug 2025 ➔ Mar 2025 | Recruiting ➔ Withdrawn | Trial primary completion date: Aug 2025 ➔ Mar 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure

EXTOR-HF: A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs (clinicaltrials.gov) - P4 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Initiation date: Jul 2024 ➔ Nov 2024

Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Initiation date: Apr 2024 ➔ Jul 2024

Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Unknown status ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: University of Texas Southwestern Medical Center

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

Immediate Release Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=26 | Not yet recruiting | Sponsor: University of Florida

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Sarfez Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: Jun 2019 ➔ Jun 2022; Trial primary completion date: Jun 2019 ➔ Jun 2022

Clinical • Enrollment open • Trial completion date • Trial primary completion date